DB
DNA icon

Dmitry Balyasny’s Ginkgo Bioworks DNA Stock Holding History

Dmitry Balyasny’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-37,977
Closed -$316K – 3022
2025
Q4 		$316K Sell
37,977
-59,941
-61% -$645K ﹤0.01% 2708
2025
Q3 		$1.43M Buy
+97,918
New +$1.17M ﹤0.01% 1969
2025
Q2 		– Sell
-169,343
Closed -$965K – 2938
2025
Q1 		$965K Buy
169,343
+88,600
+110% +$903K ﹤0.01% 2004
2024
Q4 		$793K Buy
80,743
+59,334
+277% +$509K ﹤0.01% 2032
2024
Q3 		$174K Buy
21,409
+8,317
+64% +$83.3K ﹤0.01% 2589
2024
Q2 		$175K Buy
+13,092
New +$391K ﹤0.01% 2356
2023
Q4 		– Sell
-786
Closed -$56.9K – 2563
2023
Q3 		$56.9K Sell
786
-20,852
-96% -$1.67M ﹤0.01% 2154
2023
Q2 		$1.61M Buy
21,638
+10,171
+89% +$602K ﹤0.01% 1445
2023
Q1 		$610K Buy
11,467
+10,490
+1,074% +$665K ﹤0.01% 1900
2022
Q4 		$66K Buy
+977
New +$89.9K ﹤0.01% 2310

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dmitry Balyasny's DNA Position: Q1 2026 in Review

Dmitry Balyasny sold out of Ginkgo Bioworks (DNA) in Q1 2026, closing a stake of 37,977 shares — an estimated $316K sold.

Dmitry Balyasny first reported a position in DNA in Q4 2022 and held it in 10 quarters. The position peaked at $1.61M in Q2 2023. 175 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Dmitry Balyasny reported no remaining Ginkgo Bioworks position as of Q1 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 37,977 Ginkgo Bioworks shares in Q1 2026, an estimated $316K.
  • Dmitry Balyasny first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 10 quarters.
  • Dmitry Balyasny's Ginkgo Bioworks position peaked at $1.61M in Q2 2023.
  • 175 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.